ArticleTherapeutic innovation & regulatory science2025
Leveraging Synthetic Data to Facilitate Research: A Collaborative Model for Analyzing Sensitive National Cancer Registry Data in England.
Article in Therapeutic innovation & regulatory science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world data (RWD) are increasingly recognized as critical to advancing drug development and health care delivery, with regulatory bodies increasingly recognising their value. However, stringent governance requirements, while essential for protecting patient privacy, create significant challenges for conducting research. The Cancer Analysis System (CAS), managed by National Health Service (NHS) England, includes a national cancer registry and linked health care datasets. To address data access challenges, Simulacrum, a set of publicly available synthetic datasets generated from the CAS, can be used to carry out preliminary data analysis, hypothesis generation and development of programming code that can be executed to run analyses on CAS data. This paper presents a collaborative operating model that leverages Simulacrum to enable efficient, privacy-compliant analytics. Analysis of 18 projects conducted using this model demonstrated an average duration of 2.3 months from the start of Code Development to Data Release (CDDR). By enabling researchers to conduct privacy-compliant analysis on synthetic data, this approach increases transparency by providing insights into patient-level data while reduces reliance on custodians of sensitive data. Our findings highlight how synthetic data can be leveraged to facilitate efficient research on restricted patient-level RWD, while safeguarding patient privacy. This framework offers a scalable solution for other data custodians that can enable broader use of RWD, accelerating healthcare innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.